Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Total Current Liabilities (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Total Current Liabilities for 7 consecutive years, with $16.3 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Total Current Liabilities rose 46.35% year-over-year to $16.3 million, compared with a TTM value of $16.3 million through Sep 2019, up 46.35%, and an annual FY2018 reading of $13.3 million, up 82.45% over the prior year.
  • Total Current Liabilities was $16.3 million for Q3 2019 at Larimar Therapeutics, up from $13.5 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $16.5 million in Q4 2015 and bottomed at $7.0 million in Q3 2017.
  • Average Total Current Liabilities over 5 years is $11.2 million, with a median of $11.2 million recorded in 2018.
  • The sharpest move saw Total Current Liabilities skyrocketed 181.76% in 2015, then plummeted 40.19% in 2016.
  • Year by year, Total Current Liabilities stood at $16.5 million in 2015, then tumbled by 40.19% to $9.9 million in 2016, then decreased by 26.29% to $7.3 million in 2017, then soared by 82.45% to $13.3 million in 2018, then increased by 22.79% to $16.3 million in 2019.
  • Business Quant data shows Total Current Liabilities for LRMR at $16.3 million in Q3 2019, $13.5 million in Q2 2019, and $13.7 million in Q1 2019.